6-K ·Filed Oct 13, 2026
Notable filing: 6-K
Actionable Insight • Neutral
Routine dividend reinvestment notifications, no trading signal. Monitor next quarterly earnings (likely late October/early November) for fundamental updates on revenue, EPS, and pipeline progress.
Latest settled: T+5d ⚠ clustered
GSK ▲ +9.42% at T+5d
NEUTRAL call +9.42% · α vs SPY +10.57% · entry $46.27 → $50.63
Latest observation: T+8 +10.18% FF3 residual α
T+1d
+3.46%
call +3.46% · α +4.54%
$47.87
settled 15d ago
T+5d
+9.42%
call +9.42% · α +10.57%
$50.63
settled 9d ago
T+20d
Pending
in 12d
T+60d
Pending
in 2mo
Price Chart
Loading chart...
Executive Summary
GSK filed a Form 6-K disclosing routine dividend reinvestment transactions by multiple PDMRs (including the CEO, President Europe, President International, and others) and non-executive directors. These are mechanical acquisitions of shares/ADSs following the October 8, 2026 dividend payment, not discretionary open-market purchases. The filing carries no material financial or strategic information.
Key Facts
- CEO Luke Miels acquired 23.331 ordinary shares at £17.5904 on Oct 8, 2026 via dividend reinvestment.
- President Europe Lynn Baxter acquired 297.818 ordinary shares at £17.5904 on Oct 8, 2026 via dividend reinvestment.
- President International Mike Crichton acquired 1.100 ordinary shares at £17.5904 on Oct 8, 2026 via dividend reinvestment.
- SVP & Group General Counsel James Ford acquired 2,014.345 ordinary shares at £17.5904 on Oct 8, 2026 via dividend reinvestment.
- President Corporate Development David Redfern acquired 6,532.657 ordinary shares at £17.5904 on Oct 8, 2026 via dividend reinvestment.
- President Global Supply Chain Regis Simard acquired 2,999.067 ordinary shares at £17.5904 on Oct 8, 2026 via dividend reinvestment.
- President Global Affairs Philip Thomson acquired 2,707.449 ordinary shares at £17.5904 on Oct 8, 2026 via dividend reinvestment.
- CEO ViiV Healthcare Deborah Waterhouse acquired 1,204.461 ordinary shares at £17.5904 on Oct 8, 2026 via dividend reinvestment.
- Chief Scientific Officer Tony Wood acquired 2,558.851 ordinary shares at £17.5904 on Oct 8, 2026 via dividend reinvestment.
- Independent Non-Executive Director Elizabeth McKee Anderson acquired 41 ADSs at $46.5883 on Oct 9, 2026 via dividend reinvestment.
- Senior Independent Non-Executive Director Charles Bancroft acquired 412 ADSs at $46.5883 on Oct 9, 2026 via dividend reinvestment.
- Non-Executive Director Dr Hal Barron acquired 32 ADSs at $46.5883 on Oct 9, 2026 via dividend reinvestment.
- Independent Non-Executive Director Dr Anne Beal acquired 47 ADSs at $46.5883 on Oct 9, 2026 via dividend reinvestment.
- Independent Non-Executive Director Dr Harry Dietz acquired 45 ADSs at $46.5883 on Oct 9, 2026 via dividend reinvestment.
- Independent Non-Executive Director Dr Jeannie Lee acquired 27 ADSs at $46.5883 on Oct 9, 2026 via dividend reinvestment.
- Independent Non-Executive Director Dr Vishal Sikka acquired 136 ADSs at $46.5883 on Oct 9, 2026 via dividend reinvestment.
- PCA Neil Falkingham (PCA of Lynn Baxter) acquired 169.615 ordinary shares at £17.5904 on Oct 8, 2026 via dividend reinvestment.
- PCA Kate Thomson (PCA of Philip Thomson) acquired 112.233 ordinary shares at £17.5904 on Oct 8, 2026 via dividend reinvestment.
Financial Impact
No material financial impact. All transactions are automatic dividend reinvestments with trivial aggregate value relative to GSK's market cap.
Risk Factors
- No material risks identified from this filing.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-008921 |
| Document: 0001654954-26-008921-index-headers.html | 0001654954-26-008921 |
| Document: 0001654954-26-008921-index.html | 0001654954-26-008921 |
| Document: 0001654954-26-008921.txt | 0001654954-26-008921 |
60 reports for GSK
47% Hit rate @ T+5 Went positive at some point 15 of 21 best @ T+60▲ +9.35%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 28, 2026 today | 6-K | $49.07 | awaiting T+5 | awaiting T+5 | $48.74 (−0.67%) |
Oct 26, 2026 2d ago | 6-K | $51.10 | awaiting T+5 | awaiting T+5 | $48.74 (−4.62%) |
Oct 26, 2026 2d ago | 6-K | $51.10 | awaiting T+5 | awaiting T+5 | $48.74 (−4.62%) |
Oct 26, 2026 2d ago | 6-K | $51.10 | awaiting T+5 | awaiting T+5 | $48.74 (−4.62%) |
Oct 26, 2026 2d ago | 6-K | $51.10 | awaiting T+5 | awaiting T+5 | $48.74 (−4.62%) |
Oct 21, 2026 7d ago | 6-K | $50.02 $50.94 | ▲ +1.84% | ▲ +2.28% | $48.74 (−2.56%) |
Oct 19, 2026 9d ago | 6-K | $49.46 $51.10 | ▲ +3.32% | ▲ +3.46% | $48.74 (−1.46%) |
Oct 19, 2026 9d ago | 6-K | $49.46 $51.10 | ▲ +3.32% | ▲ +3.46% | $48.74 (−1.46%) |
Oct 15, 2026 13d ago | 6-K | $49.02 $51.21 | ▲ +4.47% | ▲ +5.48% | $48.74 (−0.57%) |
Oct 14, 2026 14d ago | 6-K | $47.87 $50.02 | ▲ +4.49% | ▲ +4.04% | $48.74 (+1.82%) |
Showing 10 of 60
US Market Status
Market Closed · Opens in 3h 39m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers